» Articles » PMID: 34825008

Temporal and Quantitative Analysis of Aortic Immunopathologies in Elastase-Induced Mouse Abdominal Aortic Aneurysms

Overview
Journal J Immunol Res
Publisher Wiley
Date 2021 Nov 26
PMID 34825008
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Elastase-induced abdominal aortic aneurysm (AAA) model is widely used for aneurysmal pathogenesis and translational research. However, temporal alternations in aneurysmal histologies remain unknown. This study is aimed at analyzing temporal immunopathologies of aneurysmal aorta following experimental AAA induction.

Methods: Male C57BL/6J mice at the age of 10-14 weeks received intra-aortic infusion of elastase to induce AAAs. Aortic diameters at the baseline and indicated days after AAA induction were measured, and aortae were collected for histopathological analysis.

Results: Aorta diameters increased from 0.52 mm at the baseline levels to 0.99 mm, 1.34 mm, and 1.41 mm at days 7, 14, and 28, respectively, corresponding 90%, 158%, and 171% increases over the baseline level. Average aortic diameters did not differ between days 14 and 28. Severe elastin degradation and smooth muscle cell depletion were found at days 14 and 28 as compared to the baseline and day 7. No difference in the scores of medial elastin and SMC destruction was noted between days 14 and 28. Consistent results were found for leukocyte accumulation, neoangiogenesis, and matrix metalloproteinase expression. Twenty-eight days after AAA induction, all aneurysmal pathologies showed an attenuated trend, although most histopathological parameters did no differ between days 14 and 28.

Conclusion: Our data suggest that almost aneurysmal immunohistopathologies reach maximal 14 days following AAA induction. Analysis of day 14 histologies is sufficient for AAA pathogenesis and translational studies in elastase-induced mouse experimental AAAs.

Citing Articles

Animal models for abdominal aortic aneurysms: Where we are and where we need to go.

Tian K, Malik F, Zhao S Animal Model Exp Med. 2025; 8(3):573-577.

PMID: 39906001 PMC: 11904099. DOI: 10.1002/ame2.12572.


Cysteine Leukotriene Receptor Antagonist-Montelukast-Treatment Improves Experimental Abdominal Aortic Aneurysms in Mice.

Li K, Li M, Wei P, Tian K, Liu H, Fu W Cardiovasc Ther. 2025; 2024:8826287.

PMID: 39742015 PMC: 11617055. DOI: 10.1155/2024/8826287.


The C57BL/6N mouse substrain is a viable model of elastase-induced abdominal aortic aneurysm.

Wei P, Li K, Li M, Liu H, Xia C, Chen Y Front Cardiovasc Med. 2024; 11:1462032.

PMID: 39399516 PMC: 11466807. DOI: 10.3389/fcvm.2024.1462032.


Application and challenges of TCR and BCR sequencing to investigate T- and B-cell clonality in elastase-induced experimental murine abdominal aortic aneurysm.

Elster C, Ommer-Blasius M, Lang A, Vajen T, Pfeiler S, Feige M Front Cardiovasc Med. 2023; 10:1221620.

PMID: 38034381 PMC: 10686233. DOI: 10.3389/fcvm.2023.1221620.


The incidence rate and histological characteristics of intimal hyperplasia in elastase-induced experimental abdominal aortic aneurysms in mice.

Li M, Wei P, Li K, Liu H, Alam N, Hou H Animal Model Exp Med. 2023; 7(3):388-395.

PMID: 38017222 PMC: 11228087. DOI: 10.1002/ame2.12362.


References
1.
Mulorz J, Shayan M, Hu C, Alcazar C, Chan A, Briggs M . -Adventitial delivery of smooth muscle cells in porous collagen scaffolds for treatment of experimental abdominal aortic aneurysm. Biomater Sci. 2021; 9(20):6903-6914. PMC: 8511090. DOI: 10.1039/d1bm00685a. View

2.
Liao S, Miralles M, Kelley B, Curci J, Borhani M, Thompson R . Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg. 2001; 33(5):1057-64. DOI: 10.1067/mva.2001.112810. View

3.
Rouer M, Xu B, Xuan H, Tanaka H, Fujimura N, Glover K . Rapamycin limits the growth of established experimental abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2014; 47(5):493-500. DOI: 10.1016/j.ejvs.2014.02.006. View

4.
Fujimura N, Xiong J, Kettler E, Xuan H, Glover K, Mell M . Metformin treatment status and abdominal aortic aneurysm disease progression. J Vasc Surg. 2016; 64(1):46-54.e8. PMC: 4925242. DOI: 10.1016/j.jvs.2016.02.020. View

5.
Golledge J . Abdominal aortic aneurysm: update on pathogenesis and medical treatments. Nat Rev Cardiol. 2018; 16(4):225-242. DOI: 10.1038/s41569-018-0114-9. View